Time is of the essence

The field of cancer immunotherapy is showing great promises and, as a result, it is common to see 100-120 and sometimes 130-180 new scientific articles being published every week on this topic. It is becoming extremely time-consuming for researchers to keep up with these studies. 

ACIR prepares a free weekly summary of the most relevant and promising findings, allowing researchers to be up to date in only 20 minutes. Our goal is to allow scientists to spend more time on their research and be up to date in their knowledge to hopefully find a cure. 

We provide the following resources free-of-charge:

Since June 2017, over 1,100 researchers have subscribed to our weekly newsletter and more than 21,000 have used the resources on our website.

“The ACIR weekly newsletter is an invaluable resource for me as a cancer researcher and drug developer.  The recent explosion of Immuno-Oncology related literature makes it difficult to review everything that is published. The ACIR newsletter makes accessible the most important and significant research in IO. This allows me more time to focus on drug development and be confident that I am remaining current with a rapidly advancing field.”   

Jamie Rice, PhD, Senior Investigator, Project Lead, Silicon Therapeutics, USA

Every week, we receive emails from scientists thanking us for providing such a valuable service. 

 “As a researcher bridging the science and clinical translation of the exciting discoveries of cancer immunotherapy, I applaud the efforts of ACIR to help me, my post-docs and students, and my colleagues keep up to date on all the key innovations driving this field.  New knowledge continually refines our current thinking and ACIR keeps that new knowledge fresh and at our fingertips."                                                                                                                                                   

Catherine Wu, MD, PhD,Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School; Institute Member, Broad Institute of Harvard and MIT, USA

Will you donate to support our mission?

Every contribution counts and helps us provide a unique and much needed service to researchers in cancer immunotherapy. You donate today, they find a cure tomorrow.

The story of ACIR

After the untimely death of his wife Jan, Ed Fritsch was dedicated to do his best to help find a cure to the disease that impacted his life. Researcher by trade, he came across cancer immunotherapy and soon began working in the field. 

Unfortunately, four years later his son, Matt, passed away from melanoma. Shortly after, Ed’s family discovered that Matt, a successful engineer at SpaceX, wanted to donate his stock options to cancer research. Wanting to honor his memory, the family created the Fritsch Foundation.

Ed knew the tremendous potential that cancer immunotherapy had. With so many important advancements in the field, he thought that a service that would digest and categorize the literature would be an exceptional resource to researchers everywhere. He shared his idea with Ute Burkhardt, who was working in the field at the Dana Farber Cancer Institute, and soon after in the fall of 2015, the Fritsch Foundation launched ACIR. 

“I donate to ACIR to join the fight. It was started by one of the kindest, smartest, hardest working, and most honest people I have ever met, who also happens to have an incredibly sad story. I was close friends with his son, who shared these incredible traits. Another close friend of mine and many of my family members have similar stories. I can't sit back while people are battling this. ACIR fills the communication void by organizing and announcing research around the world in clear articles. By exposing more researchers to different studies, we are able to work together to assemble the puzzle. It is one of the most efficient ways to put donations to good use. This is a very lean and trustworthy organization. I am relieved to know it exists and am honored to be able to contribute.” -Zach


Meet some of the fundraisers that are part of this campaign

Recent Updates

Recent Donors